10-QPeriod: Q1 FY2014

IDEXX LABORATORIES INC /DE Quarterly Report for Q1 Ended Mar 31, 2014

Filed April 25, 2014For Securities:IDXX

Summary

IDEXX Laboratories, Inc. (IDXX) reported solid financial results for the first quarter of 2014, showcasing robust revenue growth driven primarily by its Companion Animal Group (CAG) segment. Total revenue increased by 8.5% year-over-year to $360.2 million, with CAG alone growing 8.9%. This growth was fueled by increases in recurring diagnostics revenue, particularly VetLab consumables and reference laboratory services, along with strong performance in customer information management and digital imaging systems. The company also saw positive contributions from its Livestock, Poultry and Dairy (LPD) segment, which grew 11.8%. Profitability also improved, with gross profit rising 9.9% to $202.1 million and operating income increasing by 14.5% to $70.0 million. Net income attributable to IDEXX stockholders reached $46.6 million, a 3.9% increase, leading to diluted earnings per share of $0.89. The company continued its commitment to shareholder returns through significant share repurchases, spending $70.3 million in the quarter. IDEXX maintained a strong liquidity position with $286.2 million in cash and cash equivalents and ample borrowing capacity, positioning it well for continued growth and strategic initiatives.

Financial Highlights

51 data points
Beta

Revenue

$360.20M

56.1% Gross Margin

Net Income

$46.59M

12.9% Net Margin

EPS (Diluted)

$0.45

Total Assets

$1.26B

Cash & Equivalents

$286.20M

Free Cash Flow

$22.22M

Financial Statements
Beta
Revenue$360.20M
Cost of Revenue$158.11M
Gross Profit$202.10M
R&D Expenses$23.11M
Operating Income$70.05M
Interest Expense$2.77M
Net Income$46.59M
EPS (Basic)$0.45
EPS (Diluted)$0.45
Shares Outstanding (Basic)103.23M
Shares Outstanding (Diluted)104.68M

Key Highlights

  • 1Total revenue increased by 8.5% to $360.2 million for the three months ended March 31, 2014, compared to the prior year period.
  • 2Companion Animal Group (CAG) revenue grew 8.9% to $301.6 million, driven by recurring diagnostics, VetLab consumables, and reference laboratory services.
  • 3Livestock, Poultry and Dairy (LPD) segment revenue showed strong growth of 11.8% to $31.4 million.
  • 4Gross profit increased by 9.9% to $202.1 million, with a gross profit margin of 56.1%.
  • 5Operating income grew 14.5% to $70.0 million.
  • 6Net income attributable to IDEXX stockholders was $46.6 million, resulting in diluted EPS of $0.89.
  • 7The company repurchased $70.3 million of its common stock during the quarter, demonstrating a commitment to shareholder returns.

Frequently Asked Questions

The primary driver of IDEXX's revenue growth is the Companion Animal Group (CAG) segment, which experienced an 8.9% increase in revenue. This growth was primarily attributed to higher volumes and increased pricing in its recurring diagnostics revenue, including VetLab consumables, reference laboratory diagnostic services, and customer information management and digital imaging systems.

IDEXX has shown improved profitability. Gross profit increased by 9.9% to $202.1 million, with a slight improvement in gross margin to 56.1%. Operating income also saw a significant increase of 14.5% to $70.0 million. Net income attributable to IDEXX stockholders increased by 3.9% to $46.6 million, leading to a diluted EPS of $0.89.

IDEXX maintained a strong liquidity position. Cash and cash equivalents stood at $286.2 million as of March 31, 2014. The company also had $134.0 million in remaining borrowing availability under its credit facility, indicating sufficient resources to fund operations and strategic growth initiatives.

IDEXX actively engaged in share repurchases, spending $70.3 million in the first quarter of 2014. This demonstrates the company's commitment to returning value to shareholders and also serves to offset the dilutive effect of its share-based compensation programs.